CRISPR THERAPEUTICS AG (CRSP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CRSP • CH0334081137

48.74 USD
+2.86 (+6.23%)
At close: Feb 6, 2026
48.79 USD
+0.05 (+0.1%)
After Hours: 2/6/2026, 8:26:35 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CRSP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While CRSP has a great health rating, there are worries on its profitability. CRSP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CRSP had negative earnings in the past year.
  • In the past year CRSP has reported a negative cash flow from operations.
  • CRSP had negative earnings in 4 of the past 5 years.
  • In the past 5 years CRSP reported 4 times negative operating cash flow.
CRSP Yearly Net Income VS EBIT VS OCF VS FCFCRSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -21.75%, CRSP is in the better half of the industry, outperforming 74.43% of the companies in the same industry.
  • The Return On Equity of CRSP (-25.49%) is better than 79.01% of its industry peers.
Industry RankSector Rank
ROA -21.75%
ROE -25.49%
ROIC N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
CRSP Yearly ROA, ROE, ROICCRSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CRSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRSP Yearly Profit, Operating, Gross MarginsCRSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRSP has been increased compared to 1 year ago.
  • The number of shares outstanding for CRSP has been increased compared to 5 years ago.
  • There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRSP Yearly Shares OutstandingCRSP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRSP Yearly Total Debt VS Total AssetsCRSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • CRSP has an Altman-Z score of 7.11. This indicates that CRSP is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.11, CRSP is in the better half of the industry, outperforming 78.24% of the companies in the same industry.
  • There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.11
ROIC/WACCN/A
WACC4.96%
CRSP Yearly LT Debt VS Equity VS FCFCRSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 16.22 indicates that CRSP has no problem at all paying its short term obligations.
  • The Current ratio of CRSP (16.22) is better than 93.13% of its industry peers.
  • CRSP has a Quick Ratio of 16.22. This indicates that CRSP is financially healthy and has no problem in meeting its short term obligations.
  • CRSP has a Quick ratio of 16.22. This is amongst the best in the industry. CRSP outperforms 93.13% of its industry peers.
Industry RankSector Rank
Current Ratio 16.22
Quick Ratio 16.22
CRSP Yearly Current Assets VS Current LiabilitesCRSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • CRSP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.30%.
  • The Revenue for CRSP has decreased by -81.10% in the past year. This is quite bad
  • CRSP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.62% yearly.
EPS 1Y (TTM)-58.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.84%
Revenue 1Y (TTM)-81.1%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%47.67%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.52% on average over the next years. This is quite good.
  • Based on estimates for the next years, CRSP will show a very strong growth in Revenue. The Revenue will grow by 179.11% on average per year.
EPS Next Y-44.51%
EPS Next 2Y2.42%
EPS Next 3Y5.9%
EPS Next 5Y15.52%
Revenue Next Year-49.23%
Revenue Next 2Y173.81%
Revenue Next 3Y163.27%
Revenue Next 5Y179.11%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRSP Yearly Revenue VS EstimatesCRSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
CRSP Yearly EPS VS EstimatesCRSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRSP. In the last year negative earnings were reported.
  • Also next year CRSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRSP Price Earnings VS Forward Price EarningsCRSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRSP Per share dataCRSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.42%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRSP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRISPR THERAPEUTICS AG

NASDAQ:CRSP (2/6/2026, 8:26:35 PM)

After market: 48.79 +0.05 (+0.1%)

48.74

+2.86 (+6.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)02-17
Inst Owners77.93%
Inst Owner Change-0.86%
Ins Owners1.57%
Ins Owner Change-0.28%
Market Cap4.64B
Revenue(TTM)38.34M
Net Income(TTM)-488.30M
Analysts76.67
Price Target72.34 (48.42%)
Short Float %23.2%
Short Ratio12.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.79%
Min EPS beat(2)8.57%
Max EPS beat(2)11%
EPS beat(4)3
Avg EPS beat(4)14.7%
Min EPS beat(4)-23.86%
Max EPS beat(4)63.08%
EPS beat(8)6
Avg EPS beat(8)210.14%
EPS beat(12)10
Avg EPS beat(12)155.51%
EPS beat(16)11
Avg EPS beat(16)115.33%
Revenue beat(2)0
Avg Revenue beat(2)-88.12%
Min Revenue beat(2)-90.21%
Max Revenue beat(2)-86.02%
Revenue beat(4)1
Avg Revenue beat(4)20.13%
Min Revenue beat(4)-90.21%
Max Revenue beat(4)343.7%
Revenue beat(8)2
Avg Revenue beat(8)-18.1%
Revenue beat(12)4
Avg Revenue beat(12)325.02%
Revenue beat(16)5
Avg Revenue beat(16)256.51%
PT rev (1m)-9.79%
PT rev (3m)-12.14%
EPS NQ rev (1m)3.14%
EPS NQ rev (3m)-2.6%
EPS NY rev (1m)0.15%
EPS NY rev (3m)0.01%
Revenue NQ rev (1m)-20.31%
Revenue NQ rev (3m)-75.97%
Revenue NY rev (1m)-50.22%
Revenue NY rev (3m)-73.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 121.16
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-4.48
EYN/A
EPS(NY)-4.16
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.17
OCFYN/A
SpS0.4
BVpS20.1
TBVpS20.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.75%
ROE -25.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 137.47%
Cap/Sales 66.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.22
Quick Ratio 16.22
Altman-Z 7.11
F-Score2
WACC4.96%
ROIC/WACCN/A
Cap/Depr(3y)74.64%
Cap/Depr(5y)175.56%
Cap/Sales(3y)1036.11%
Cap/Sales(5y)1149.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.84%
EPS Next Y-44.51%
EPS Next 2Y2.42%
EPS Next 3Y5.9%
EPS Next 5Y15.52%
Revenue 1Y (TTM)-81.1%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%47.67%
Revenue Next Year-49.23%
Revenue Next 2Y173.81%
Revenue Next 3Y163.27%
Revenue Next 5Y179.11%
EBIT growth 1Y-43.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.2%
EBIT Next 3Y5.31%
EBIT Next 5Y20.04%
FCF growth 1Y-11.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.97%
OCF growth 3YN/A
OCF growth 5YN/A

CRISPR THERAPEUTICS AG / CRSP FAQ

Can you provide the ChartMill fundamental rating for CRISPR THERAPEUTICS AG?

ChartMill assigns a fundamental rating of 3 / 10 to CRSP.


What is the valuation status for CRSP stock?

ChartMill assigns a valuation rating of 0 / 10 to CRISPR THERAPEUTICS AG (CRSP). This can be considered as Overvalued.


What is the profitability of CRSP stock?

CRISPR THERAPEUTICS AG (CRSP) has a profitability rating of 1 / 10.


Can you provide the financial health for CRSP stock?

The financial health rating of CRISPR THERAPEUTICS AG (CRSP) is 8 / 10.